Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20932682 | 0.99 | LMNA (0.44) | LMNAP2RX7PKML3MBTL1IDO1 | |
| Bromide SCHEMBL20920041 | 0.89 | P2RX7 (0.47) | LMNAP2RX7PKML3MBTL1ALDH1A1 | |
| Bromide SCHEMBL22263142 | 0.79 | LMNA (0.43) | LMNAIDO1ALDH1A1SMN1; SMN2HPGD | |
| Bromide SCHEMBL22263160 | 0.78 | IDO1 (0.50) | LMNAIDO1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL22275592 | 0.77 | LMNA (0.44) | LMNAIDO1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL22275816 | 0.76 | IDO1 (0.51) | LMNAIDO1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL22275936 | 0.75 | P2RX7 (0.47) | LMNAP2RX7L3MBTL1ALDH1A1TP53 | |
| SCHEMBL2111658 | 0.75 | P2RX7 (0.47) | LMNAP2RX7ALDH1A1TP53SMN1; SMN2 | |
| Bromide SCHEMBL22263118 | 0.74 | LMNA (0.53) | LMNAPKMIDO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18790103 | 0.73 | P2RX7 (0.45) | LMNAP2RX7ALDH1A1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092020-A1 | IDO/TDO Inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12209079-B2 | IDO/TDO inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-01-28 | — | — | US | disclosed |
| US-20220380305-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. | 2022-12-01 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209079-B2 | IDO/TDO inhibitor | IDO1, IDO2, TDO2 | LMNA 4867/4885P2RX7 4501/4885PKM 3515/4885 |
| US-20200239452-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | LMNA 4867/4885P2RX7 4501/4885PKM 3515/4885 |
| US-20250092020-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | LMNA 4867/4885P2RX7 4501/4885PKM 3515/4885 |
| US-20220380305-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | LMNA 4875/4885P2RX7 3190/4885PKM 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.